Shelter PharmaBOM:543963 +0.66%66 EBITDA Margin % is 16.26% as of Mar. 2026, which is 7% below its 10-year median of 17.42. GuruFocus rates BOM:543963 with a GF Score™ of 66/100 and a GF Value™ of ₹57.84 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 956 Drug Manufacturers companies, Shelter Pharma ranks better than 62.45% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Shelter Pharma's EBITDA for the
six
months ended in Mar. 2026 was ₹64.8 Mil. Shelter Pharma's Revenue for the
six
months ended in Mar. 2026 was ₹398.4 Mil. Therefore, Shelter Pharma's EBITDA margin for the quarter that ended in Mar. 2026 was 16.26%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Shelter Pharma EBITDA Margin % Related Terms
Shelter Pharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Shelter Pharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543963 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shelter Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shelter Pharma EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shelter Pharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Shelter Pharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shelter Pharma (BOM:543963) has a EBITDA Margin % of 16.26% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shelter Pharma and its competitors. This is near median its historical median of 17.42. According to the industry distribution chart, Shelter Pharma ranks #359 out of 956 companies in the Drug Manufacturers industry, placing it in the top 37.6%.
Is Shelter Pharma's EBITDA Margin % too high?
Shelter Pharma's current EBITDA Margin % of 16.26% is near median its 10-year median of 17.42. The Drug Manufacturers industry median EBITDA Margin % is 12.52. Shelter Pharma's value of 16.26% is 29.9% above this industry median. Based on the distribution chart, Shelter Pharma ranks #359 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Shelter Pharma has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Shelter Pharma's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shelter Pharma ranks #359 out of 956 companies for EBITDA Margin %. This puts Shelter Pharma in the upper half of its industry. The industry median EBITDA Margin % is 12.52. Shelter Pharma's value of 16.26% is 29.9% above this benchmark. While the company's 10-year median is 17.42 vs. the industry median of 12.52, Shelter Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shelter Pharma's current EBITDA Margin % of 16.26% is 29.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shelter Pharma and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shelter Pharma's current EBITDA Margin % is 16.26%, which is near median its own 10-year median of 17.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shelter Pharma stock overvalued right now?
Based on GuruFocus' analysis, Shelter Pharma (BOM:543963) is currently considered Possible Value Trap. The stock's GF Value™ is ₹57.84, compared to a current price of ₹29.05 — trading 49.8% below its estimated fair value. The current EBITDA Margin % is 16.26%, which is near median its 10-year median of 17.42 and 29.9% above the Drug Manufacturers industry median of 12.52. Shelter Pharma's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Shelter Pharma (BOM:543963), the current EBITDA Margin % is 16.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shelter Pharma (BOM:543963) Overvalued in 2026?
Based on GuruFocus' analysis, Shelter Pharma stock appears to be undervalued.
The current stock price of ₹29.05 is trading 49.8% below its estimated GF Value™ of ₹57.84.
GuruFocus considers Shelter Pharma to be Possible Value Trap.
Key valuation signals for BOM:543963:
EBITDA Margin %: 16.26% (near median its 10-year median of 17.42)
GF Value™: ₹57.84 vs. price of ₹29.05 (49.8% below fair value)
Industry Position: 29.9% above the Drug Manufacturers median (#359 of 956)
No single metric tells the full story. See the BOM:543963 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shelter Pharma Ltd focuses in manufacturing herbal products with a well-built presence in Human Pharma as well as the Veterinary space. It is present in majority of the non-critical segments of human and veterinary pharma through its well-spread portfolio. Its products include tablets, syrups, baby drops, barley water, oils, powders, ointments, etc.
66GF Score
Get the complete analysis for BOM:543963
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543963 has been successfully added to your 
